Capucine Van Rechem, PhDMassachusetts General Hospital2014 Skacel Family Scholar Copy Gain and Resistance: Uncovering Roles for Epigenetic Regulation in Ovarian Cancer A major issue in the treatment of ovarian cancer is the development of resistance to standard chemotherapy. Such drug resistance has been linked to the gain of a specific genomic region, 1q12-1q21. Dr. Van […]
Read More
Michael Goldberg, PhDDana-Farber Cancer Institute2014 Kirwin-Hinton Family Scholar Unraveling the role of ATR in DNA repair and ovarian cancer therapy The majority of cancer therapies attempt to kill tumor cells using drugs that are often toxic. Many patients relapse because residual cells can establish new drug-resistant tumors. Unlike traditional therapies, the immune system can adapt […]
Read More
Alexandra Snyder Charen, MDSloan-Kettering Institute for Cancer Researchr Chemotherapy, Somatic Mutations, and Neoantigens in Ovarian Cancer Immunotherapy is a new treatment that boosts a patient’s immune system to attack ovarian cancer cells. Dr. Synder Charen’s lab has already shown in melanoma that when a tumor has a large number of genetic abnormalities (mutations), the immune […]
Read More
Benjamin Izar, MD, PhDDana-Farber Cancer Institute Single-cell transcriptome analysis of treatment-resistant ovarian cancer and new strategies for drug discovery Dr. Izar will be studying in fine detail the molecular changes that take place from the time that ovarian cancer cells respond to platinum chemotherapy to when they become resistant. He will employ an innovative genetic […]
Read More
Mark Eckert, PhDUniversity of Chicago Targeting T-LAK cell-originated protein kinase (TOPK) for ovarian cancer therapy Ovarian cancer is one of the most lethal cancers due to a lack of effective therapies. Dr. Eckert’s lab recently found that the protein T-LAK cell-originated protein kinase (TOPK) is expressed in ovarian cancer cells, but not most normal tissues. […]
Read More
Remi Buisson, PhDMassachusetts General Hospital Unraveling the role of ATR in DNA repair and ovarian cancer therapy Proteins involved in the surveillance of genomic integrity, including BRCA1, BRCA2, and PALB2, help detect damage to DNA in cells and ensure that repairs are made when needed. Cells with mutations in BRCA1, BRCA2, and PALB2 have been […]
Read More
Erin George, MDUniversity of Pennsylvania2016 Skacel Family Scholar Targeting the ATR/CHK1 pathway in high grade serous ovarian cancer with ATR inhibitors New treatments are needed for recurrent ovarian cancer, a subset of which is more aggressive than the original cancer and has no effective treatment. Aggressive recurrent cancers rely on DNA repair pathways, involving proteins […]
Read More
Yasuto Kinose, M.D., Ph.D.University of PennsylvaniaPhiladelphia, PA, United States2018 SKACEL FAMILY SCHOLAR Project: Evaluation of a novel combination therapy in clear cell ovarian cancer orthotopic patient-derived xenograft models Research Area: Novel Therapy, Cancer Biology Summary:While clear cell ovarian cancer is a relatively rare subtype of ovarian cancer, it is also the most difficult to treat in advanced […]
Read More
Erin George, MDUniversity of Pennsylvania2019 Lynda’s Fund Scholar Award Strategies to optimize drug tolerability without compromising efficacy Most women with ovarian cancer present with advanced stage disease. Large surgeries and toxic chemotherapies are the mainstay of treatment and, despite advances in medicine, most ovarian cancers return. Every tumor is unique in its biology, allowing for […]
Read More
Sarah Beth Gitto, PhDUniversity of Pennsylvania2019 Scientific Scholar Award Priming the TME with anti-VEGF to enhance the efficacy of dual checkpoint inhibition in PARPi-resistant OC Recent studies have shown that the use of the PARP inhibitor olaparib increases survival of ovarian cancer. Unfortunately, most patients will become resistant to PARP inhibitors, thus novel treatment strategies […]
Read More